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Why asthma still kills (Royal College of Physicians, 2015) is the National Review of Asthma Deaths' 
(NRAD) first national investigation of asthma deaths in the UK and the largest study worldwide to 
date. The primary aim was to understand the circumstances surrounding asthma deaths in order to 
identify avoidable factors and make recommendations to improve care and reduce the number of 
deaths. 
Some of the recommendations involve prescribing and medicines use.  One of these specifically 
states “All asthma patients who have been prescribed more than 12 short-acting reliever inhalers in 
the previous 12 months should be invited for urgent review of their asthma control, with the aim of 
improving their asthma through education and change of treatment if required.” 
The reason for this is that over-use of short acting relievers can be an indication of uncontrolled 
asthma.   An additional concern due to over-use can be explained by the pharmacology of short-
acting relievers.  These medicines, such as salbutamol and terbutaline, are beta-2 receptor agonists 
see BNF (BMA&RPS, 2016).  Over use of agonist drugs leads to “down-regulation” of receptors and 
the outcome of this to the patient is that when needed in emergency the therapeutic effect may be 
insufficient to relieve their symptoms.  Also, over-use of medicines can lead to side effects (eg 
palpitations or anxiety), and is a waste of NHS resources. 
Imagine a scenario where you are working with your practice pharmacist to address this matter.   
The pharmacist has searched the practice computer system and identified a list of 29 patients who 
have received more than 12 prescriptions for Short acting beta-agonists (SABAs) in the last 12 
months.  You have 1450 patients on the asthma register.   
Question 1 
What percentage of asthma patients need to be invited for an urgent review? 2% 
Most of these patients are receiving repeat prescriptions for “salbutamol 100microgram per 
metered dose 200 dose cfc-free inhaler”.     
Question 2 
If a patient has used 12 of these in a 12 month period, how many doses per day does this indicate 
they have used? 
a. Less than 2 puffs 
b. 3 to 5 puffs 
c. 6 to 8 puffs 
Question 3 
In well controlled asthma SABAs should not be needed more than twice per week.  Assume your 
patient uses 2 puffs twice a week.   
How long should one salbutamol 200 dose inhaler last? 
a. Less than 4 months 
b. 5-10 months 
c. More than 11 months 
Question 4 
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You notice that some patients are being issued with two salbutamol 200 dose inhalers per month.  
How many doses per day does this indicate that they are using? 
a. 6-10 puffs 
b. 11-15 puffs 
c. 16-20 puffs 
Many patients with asthma also  require an inhaled corticosteroid (ICS).  The Medicines and 
Healthcare Product Regulatory Agency recommends that beclomethasone-containing metered dose 
inhalers (MDIs) are prescribed by brand because the available products are not interchangeable.  
Two brands are available.  Qvar is an ICS with an ultra-fine particle size.  This means that the 
prescribed dose should be HALF of the standard formulation Clenil MDI.   
Question 5 
Imagine your local formulary recommends Qvar as the first line ICS of choice.  Calculate the Qvar 
dose that is equivalent to these doses of Clenil (you may need to use your BNF if you are not familiar 
with the available Qvar presentations): 
a. Clenil 100micrograms per dose, 2 puffs twice a day  
Qvar 50 micrograms per dose, 2 puffs twice a day 
b. Clenil 200micrograms per dose, 2 puffs twice a day 
Qvar 100 micrograms per dose, 2 puffs twice a day 
 
 
Some  asthma patients additionally require a Long Acting Beta Agonist (LABA) alongside their ICS.  
Imagine the following LABA/ICS combination products are available to you: 
Fostair 100/6 MDI.   
DuoResp 160/4.5 Spiromax 
Symbicort 200/6 Turbohaler 
Question 6 
Use the BNF to find out the constituents of each of these products then state which of the following 
ICS/LABA combinations is equipotent: 
 
a. Fostair 100/6 1 puff twice a day  | Symbicort 200/6 1 puff twice a day | Duoresp 160/4.5 1 
puff twice a day 
b. Fostair 100/6 2 puffs twice daily | Symbicort 200/6 1 puff twice a day | Duoresp 160/4.5 1 
puff twice a day 
c. Fostair 100/6 2 puffs twice a day | Symbicort 200/6 1 puff twice a day | Duoresp 160/4.5 2 
puffs twice a day 
